Global Stem Cell Therapy Market 2017-2021

幹細胞治療の世界市場2017-2021

◆タイトル:Global Stem Cell Therapy Market 2017-2021
◆商品コード:IRTNTR11121
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年1月25日
◆ページ数:70
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、幹細胞治療の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、幹細胞治療の世界市場規模及び予測、用途別分析、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About stem cell therapyStem cell therapy is the use of stem cells for the treatment or prevention of a disease or condition. Bone marrow transplant is the widely-used stem cell therapy, followed by therapies derived from umbilical cord blood. Research is being undertaken to develop various sources (such as cord blood cells, bone marrow, and skin) for stem cells, and to apply them to various disorders like neurodegenerative diseases and conditions such as heart disease, diabetes, and other conditions.

Technavio’s analysts forecast the global stem cell therapy market to grow at a CAGR of 36.52% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global stem cell therapy market for 2017-2021. To calculate the market size, the report considers the sales of stem cell therapy products/segments in the market.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Stem Cell Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Holostem Advanced Therapies
• JCR Pharmaceuticals
• Organogenesis
• Osiris Therapeutics
• Vericel

[Other prominent vendors]
• AbbVie
• American CryoStem
• AM-Pharma
• Anterogen
• apceth Biopharma
• Astellas Pharma
• Athersys
• Baxter International
• Beike Biotechnology
• BIOTIME
• bluebird bio
• Bristol-Myers Squibb
• BrainStorm Cell Therapeutics
• Brainxell
• Caladrius Biosciences
• Cellular Biomedicine Group
• Cellular Dynamics International (a subsidiary of Fujifilm)
• Cesca Therapeutics
• CHA Biotech
• Chugai Pharmaceutical
• Citospin
• Corestem
• Cytori Therapeutics
• Daiichi Sankyo
• Fujifilm
• Gamida Cell
• Global Stem Cells Group
• Grupo Ferrer Internacional
• GlaxoSmithKline
• Hemostemix
• Histocell
• International Stem Cell
• Ivy Institute of Stem Cells
• Japan Regenerative Medicine
• Kangstem Biotech
• Kiadis Pharma
• Laboratorios Salvat
• MEDIPOST
• Mesoblast
• Nuo Therapeutics
• Opsis Therapeutics
• Osiris Therapeutics
• Pharmicell
• Pluristem Therapeutics
• Promethera Biosciences
• Q Therapeutics
• ReNeuron
• RHEACELL
• Salus Medical Solutions
• Sangamo Therapeutics
• Shire
• Steminent Biotherapeutics
• Sumitomo Dainippon Pharma
• Taiwan Bio Therapeutics
• Takeda Pharmaceutical
• Teva Pharmaceutical Industries
• Thoratec Corporation
• TiGenix
• Translational Biosciences
• TWO CELLS
• U.S. Stem Cell
• ViaCyte
• VistaGen Therapeutics

[Market driver]
• Increase in federal funding in stem cell therapy
• For a full, detailed list, view our report

[Market challenge]
• Stringent regulatory environment affecting the product approvals
• For a full, detailed list, view our report

[Market trend]
• Evolution of new destinations in the development of stem cell therapies
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Key market highlights

PART 05: Understanding of stem cell therapy
• History of stem cell research

PART 06: Ethical issues and regulatory landscape
• Ethical issues of stem cell research at different phases of research

PART 07: Key clinical trials
• Attractive clinical trial locations to invest
• Commercially attractive therapy areas to invest

PART 08: Market landscape
• Market overview
• Five forces analysis

PART 09: Market segmentation by therapy
• Allogeneic stem cell therapy
• Autologous stem cell therapy

PART 10: Market segmentation by applications
• Dermatology
• Musculoskeletal
• Cardiovascular

PART 11: Geographical segmentation
• Stem cell therapy market in Americas
• Stem cell therapy market in EMEA
• Stem cell therapy market in APAC

PART 12: Market drivers
• Limitations in traditional organ transplantations fueling the demand for stem cell therapies
• Increase in federal funding in stem cell therapy
• Growing demand for personalized medicine
• Increasing demand to develop effective drugs for cardiology and degenerative disorders

PART 13: Impact of drivers

PART 14: Market challenges
• Stringent regulatory environment affecting the product approvals
• Critical ethical challenges with respect to stem cell research
• High cost of clinical trials and failure rate in clinical trials

PART 15: Impact of drivers and challenges

PART 16: Market trends
• Evolution of new destinations in the development of stem cell therapies
• Increasing inorganic growth strategies such as acquisitions and licensing agreements
• Growing focus on the development of drugs for emerging applications
• Increasing investments from private enterprises likely to fuel market growth

PART 17: Vendor landscape
• Competitive scenario

PART 18: Key vendor analysis
• Holostem Advanced Therapies
• JCR Pharmaceuticals
• Organogenesis
• Osiris Therapeutics
• Vericel1
• Other prominent vendors4

PART 19: Appendix7
• List of abbreviations7

PART 20: Explore Technavio9

[List of Exhibits]

Exhibit 01: Developments in stem cell research
Exhibit 02: Ethical issues faced by various institutes at different phases of cell therapy research
Exhibit 03: Stem cell research policies in Americas
Exhibit 04: Stem cell research policies in EMEA
Exhibit 05: Stem cell research policies in APAC
Exhibit 06: Historical trend of pipeline candidates in different phases
Exhibit 07: Snapshot of pipeline trends in stem cell therapy market
Exhibit 08: Pipeline landscape by therapeutic area 2016
Exhibit 09: Pipeline by development phase 2016
Exhibit 10: Pipeline snapshot in key therapy areas
Exhibit 11: Brief overview of attractive clinical trial locations, therapy areas, and cell types
Exhibit 12: Key clinical trials
Exhibit 13: Global stem cell therapy market snapshot
Exhibit 14: Key marketed products and their company
Exhibit 15: Key vendors with robust Phase III pipeline
Exhibit 16: Global stem cell therapy market 2016-2021 ($ millions)
Exhibit 17: Opportunity analysis in global stem cell therapy market
Exhibit 18: Five forces analysis
Exhibit 19: Global stem cell therapy market segmentation by therapy 2016
Exhibit 20: Global allogeneic stem cell therapy market 2016-2021 ($ millions)
Exhibit 21: Opportunity analysis of allogeneic stem cell therapy market
Exhibit 22: Global autologous stem cell therapy market 2016-2021 ($ millions)
Exhibit 23: Opportunity analysis of autologous stem cell therapy market
Exhibit 24: Global stem cell therapy market segmentation by application 2016
Exhibit 25: Overview of dermatology in stem cell therapy market
Exhibit 26: Overview of musculoskeletal in regenerative medicine market
Exhibit 27: Overview of cardiovascular in stem cell therapy market
Exhibit 28: Segmentation of global stem cell therapy market based on geography 2016 and 2021
Exhibit 29: Stem cell therapy market revenue by geography 2016-2021 ($ millions)
Exhibit 30: Market scenario in Americas
Exhibit 31: Stem cell therapy market in Americas ($ millions)
Exhibit 32: Market scenario in EMEA
Exhibit 33: Stem cell therapy market in EMEA ($ millions)
Exhibit 34: Market scenario in APAC
Exhibit 35: Stem cell therapy market in APAC ($ millions)
Exhibit 36: Key stem cell therapy market developments in Japan by global vendors 2015
Exhibit 37: NIH: YoY and growth rate of spending toward stem cell research ($ billions)
Exhibit 38: Breakdown of CIRM funding in various stem cell research funding in 2014 ($ billions)
Exhibit 39: Active programs under CIRM 2014
Exhibit 40: Details of EC funding
Exhibit 41: Impact of drivers
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Regulatory guidelines in Japan
Exhibit 44: Key inorganic growth strategies in global stem cell therapy market
Exhibit 45: Competitive structure analysis of global stem cell therapy market 2016
Exhibit 46: Competitive analysis of global stem cell therapy market
Exhibit 47: Some of the key approvals in global stem cell therapy
Exhibit 48: Strategic success factors of companies in global stem cell therapy market
Exhibit 49: Holostem Advanced Therapies: Key highlights
Exhibit 50: Holostem Advanced Therapies: Strength assessment
Exhibit 51: Holostem Advanced Therapies: Strategy assessment
Exhibit 52: Holostem Advanced Therapies: Opportunity assessment
Exhibit 53: JCR Pharmaceuticals: Strength assessment
Exhibit 54: JCR Pharmaceuticals: Strategy assessment
Exhibit 55: JCR Pharmaceuticals: Opportunity assessment
Exhibit 56: Organogenesis: Key highlights
Exhibit 57: Organogenesis: Strength assessment
Exhibit 58: Organogenesis: Strategy assessment
Exhibit 59: Organogenesis: Opportunity assessment
Exhibit 60: Osiris Therapeutics: Key highlights
Exhibit 61: Osiris Therapeutics: Strength assessment
Exhibit 62: Osiris Therapeutics: Strategy assessment
Exhibit 63: Osiris Therapeutics: Opportunity assessment
Exhibit 64: Vericel: Key highlights
Exhibit 65: Vericel: Strength assessment
Exhibit 66: Vericel: Strategy assessment
Exhibit 67: Vericel: Opportunity assessment



【掲載企業】

Holostem Advanced Therapies, JCR Pharmaceuticals, Organogenesis, Osiris Therapeutics, Vericel, AbbVie, American CryoStem, AM-Pharma, Anterogen, apceth Biopharma, Astellas Pharma, Athersys, Baxter International, Beike Biotechnology, BIOTIME, bluebird bio, Bristol-Myers Squibb, BrainStorm Cell Therapeutics, Brainxell, Caladrius Biosciences, Cellular Biomedicine Group, Cellular Dynamics International (a subsidiary of Fujifilm), Cesca Therapeutics, CHA Biotech, Chugai Pharmaceutical, Citospin, Corestem, Cytori Therapeutics, Daiichi Sankyo, Fujifilm, Gamida Cell, Global Stem Cells Group, Grupo Ferrer Internacional, GlaxoSmithKline, Hemostemix, Histocell, International Stem Cell, Ivy Institute of Stem Cells, Japan Regenerative Medicine, Kangstem Biotech, Kiadis Pharma, Laboratorios Salvat, MEDIPOST, Mesoblast, Nuo Therapeutics, Opsis Therapeutics, Osiris Therapeutics, Pharmicell, Pluristem Therapeutics, Promethera Biosciences, Q Therapeutics, ReNeuron, RHEACELL, Salus Medical Solutions, Sangamo Therapeutics, Shire, Steminent Biotherapeutics, Sumitomo Dainippon Pharma, Taiwan Bio Therapeutics, Takeda Pharmaceutical, Teva Pharmaceutical Industries, Thoratec Corporation, TiGenix, Translational Biosciences, TWO CELLS, U.S. Stem Cell, ViaCyte, VistaGen Therapeutics.

【資料のキーワード】

幹細胞治療

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[幹細胞治療の世界市場2017-2021] (Global Stem Cell Therapy Market 2017-2021 / IRTNTR11121)販売に関する免責事項
[幹細胞治療の世界市場2017-2021] (Global Stem Cell Therapy Market 2017-2021 / IRTNTR11121)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆